Compare STVN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | CPRX |
|---|---|---|
| Founded | 1949 | 2002 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 2021 | 2006 |
| Metric | STVN | CPRX |
|---|---|---|
| Price | $17.50 | $31.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $25.67 | ★ $35.00 |
| AVG Volume (30 Days) | 500.4K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $9.67 | $9.20 |
| Revenue Next Year | $9.99 | $10.51 |
| P/E Ratio | ★ $27.15 | $62.42 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $12.89 | $19.05 |
| 52 Week High | $28.00 | $32.56 |
| Indicator | STVN | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 73.13 |
| Support Level | $13.58 | $22.24 |
| Resistance Level | $19.05 | $31.29 |
| Average True Range (ATR) | 0.78 | 0.46 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 40.84 | 97.66 |
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.